Pfizer and its Wyeth and Pharmacia & Upjohn units have resolved about 46 percent of suits that claimed the companies’ hormone-replacement medicines, including Prempro, Prempro and Provera, caused breast cancer, according to the Securities and Exchange Commission filing. Pfizer said it added $68 million to the $772 million it already reserved for the cases according to Bloomberg. The latest revelation comes after a $72.6 million dollar jury verdict against Pfizer and its units Wyeth and

William Maisel, deputy director of the FDA Center for Devices, stated “The clinical effectiveness of surgical mesh for transvaginal repair of pelvic organ prolapse has not been demonstrated,” this according to Bloomberg. In response Johnson & Johnson, and other manufactures of vaginal mesh products have agreed to more safety studies as well as further labeling changes to properly inform potential recipients of the true risks and the alleged benefits of vaginal mesh products. Besides Johnson

The New York Times reports that the government’s system for regulating many medical devices, like artificial hips, should be abandoned and replaced because it fails to examine their safety and effectiveness before sale, according to one of the nation’s top scientific groups. The report calls for and integrated premarket and post-market approach to insure that a device is safe and effective for the life of a device. As expected the medical device industry rejected the